These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 36498887)

  • 1. AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature.
    Spiezia AL; Carotenuto A; Iovino A; Moccia M; Gastaldi M; Iodice R; Tedeschi E; Petracca M; Lavorgna L; d'Ambrosio A; Brescia Morra V; Lanzillo R
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of serostatus in pediatric neuromyelitis optica spectrum disorders: A nationwide multicentric study.
    Solmaz I; Öncel IH; Konuşkan B; Erol I; Orgun LT; Yılmaz Ü; Ünalp A; Atasoy E; Aksoy E; Yılmaz D; Öztürk M; Karaca NB; Yılmaz S; Yiş U; Dündar NO; Parlak Ş; Vural A; Günbey C; Anlar B
    Mult Scler Relat Disord; 2023 Sep; 77():104847. PubMed ID: 37393803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
    J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
    Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
    [No Abstract]   [Full Text] [Related]  

  • 17. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients.
    ZhangBao J; Huang W; Zhou L; Wang L; Chang X; Lu C; Zhao C; Lu J; Quan C
    Eur J Neurol; 2021 Apr; 28(4):1308-1315. PubMed ID: 33220172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
    Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.
    Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
    J Neurol Sci; 2022 Jun; 437():120269. PubMed ID: 35483239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab.
    Gou B; Yang P; Feng J; Li Y; Huang G; Shi J; Wen L; Guo X; Zheng P; Yu G
    J Neuroimmunol; 2023 Mar; 376():578035. PubMed ID: 36716560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.